Riazi M, Moghimi S, Najmi Z, Ghaffari R
Farabi Eye Research Center, Department of ophthalmology, Tehran University of Medical Sciences, Tehran, Iran.
Eye (Lond). 2008 Nov;22(11):1419-24. doi: 10.1038/eye.2008.271. Epub 2008 Aug 29.
To evaluate the efficacy and safety of Artisan-Verysise intraocular lens (IOL) secondarily implanted for aphakic correction in post-traumatic vitrectomized eyes.
Postoperative outcomes of secondary implantation of an iris-supported Artisan IOL in 17 unilateral aphakic patients with previous pars plana vitrectomy secondary to posterior segment trauma were evaluated prospectively. Eyes had vitrectomized in previous 6-60 months. After complete ophthalmologic examination, IOL implantation was performed through a scleral tunnel incision. Patients were followed for visual outcome, endothelial cell density (ECD) and occurrence of complications. Uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), spherical equivalents (SE), and ECD were compared before and after IOL insertion.
Patients' postoperative mean follow-up were 14.65+/-5.21 months. UCVA improved in all patients. (0.03+/-0.1 preoperatively vs 0.45+/-0.29 postoperatively, P=0.0001). However improvement of BCVA was not significant. Mean postoperative SE was 0.84+/-1.32 D, whereas it was 10.85+/-1.70 D preoperatively (P=0.0001). SE was within +/-2.00 D of emmetropia in 16 eyes (94.1%). Mean endothelial cell loss was 8.1% in first 6 postoperative months.All eyes achieved the desired anatomic results. No intraoperative complications occurred in any of our cases. Complications were transient pigmented precipitates (three cases), choroidal detachment (one case), and transient vitreous haemorrhage (one case).
Secondary Artisan IOL implantation is an effective and safe procedure to correct aphakia in vitrectomized eyes without capsular support after trauma. Considering good visual rehabilitation and low rate of complications, this procedure is recommended in vitrectomized eyes.
评估Artisan-Verysise人工晶状体(IOL)二期植入用于外伤性玻璃体切除术后无晶状体眼矫正的有效性和安全性。
前瞻性评估17例因前段外伤继发扁平部玻璃体切除术后的单侧无晶状体患者二期植入虹膜支撑型Artisan人工晶状体的术后结果。患者在过去6至60个月内行玻璃体切除术。在完成全面眼科检查后,通过巩膜隧道切口植入人工晶状体。对患者进行视力结果、内皮细胞密度(ECD)及并发症发生情况的随访。比较人工晶状体植入前后的未矫正视力(UCVA)、最佳矫正视力(BCVA)、球镜等效度(SE)和ECD。
患者术后平均随访时间为14.65±5.21个月。所有患者的UCVA均有改善(术前为0.03±0.1,术后为0.45±0.29,P = 0.0001)。然而,BCVA的改善并不显著。术后平均SE为0.84±1.32 D,而术前为10.85±1.70 D(P = 0.0001)。16只眼(94.1%)的SE在正视眼±2.00 D范围内。术后前6个月平均内皮细胞损失率为8.1%。所有眼均获得了理想的解剖学结果。我们所有病例均未发生术中并发症。并发症包括短暂性色素沉着(3例)、脉络膜脱离(1例)和短暂性玻璃体出血(1例)。
二期植入Artisan人工晶状体是一种有效且安全的方法,可用于矫正外伤后无晶状体且无囊膜支撑的玻璃体切除术后眼的无晶状体状态。鉴于良好的视力康复及低并发症发生率,推荐在玻璃体切除术后眼中采用该手术。